Press Releases

Philanthropist, fundraiser and civic leader Anne D. Gioia has been reappointed to a seventh term on the Roswell Park Comprehensive Cancer Center Board of Directors. A former teacher who co-founded the Roswell Park Alliance Foundation after experiencing a devastating personal loss, she was reappointed to the board by state Sen. John J. Flanagan, New York State Senate Majority Leader, based on the recommendations of state Sens. Patrick Gallivan and Michael H. Ranzenhofer.

Roswell Park Cancer Institute and the Buffalo Sabres are teaming up to offer FREE skin cancer screening examinations and education on Thursday, May 11 from 3 p.m. to 7 p.m. at KeyBank Center.

Hypertension, or high blood pressure, may come with a plus side, at least for a subset of women with ovarian cancer.

Cancer survivor and health professional Elyse NeMoyer has been reappointed to a second three-year term on the Roswell Park Comprehensive Cancer Center Board of Directors.

Scientifically compelling breast cancer clinical-trial research is the focus of the 5th U.S.–Japan Clinical Trials in Oncology Workshop, to be led in part by Kazuaki Takabe, MD, Professor, Alfiero Foundation Endowed Chair in Breast Oncology and Clinical Chief of Breast Surgery at Roswell Park Cancer Institute. 

BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center researchers plan to test a novel adoptive cell immunotherapy platform in phase I/II clinical trials after seeing promising results in preclinical studies.

Roswell Park Cancer Institute researchers have identified a gene that influences metastasis in prostate cancer, and may help clinicians to identify aggressive prostate tumors before they progress and spread to other organs. 

John Krolewski, MD, PhD, has been appointed as Chair of the Department of Cancer Genetics and Genomics and Co-Leader of the Cancer Center Support Grant (CCSG) Genetics and Genomics Program at Roswell Park Comprehensive Cancer Center.

Tamoxifen is widely used for the treatment of women diagnosed with certain types of early and advanced breast cancers, but not all patients will benefit from it. A team from Roswell Park Cancer Institute and Northwestern University examined the mechanisms behind tamoxifen resistance.